ticlopidine
Small molecule targets CYP2B6, CYP2D6, P2RY12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TICLID | — | 2001-04-18 | fda.gov ↗ |
| Approved | US (FDA) | TICLID | — | 1991-10-31 | fda.gov ↗ |
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03298906 | Sep → Nov 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02133989 | Jun 2014 → Dec 2017 | carotid stenosis | Samsung Medical Center | Unknown | Missed primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT01514227 | Dec 2011 → Jun 2016 | coronary artery disorder | Associations for Establishment of Evidence in Interventions | Completed | Met primary |
| Phase 4 | NCT00963781 | Aug 2009 → Aug 2013 | coronary thrombosis | Scripps Health | Completed | No outcome recorded |
| Phase 4 | NCT00004727 | — | cerebral infarction | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01212302 | Oct 2008 → Mar 2010 | coronary artery disorder | Ruhr University of Bochum | Completed | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 2 | NCT01103440 Background | Apr 2007 → Jun 2009 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 3 | NCT01510327 Background | Oct 2009 → Feb 2010 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00862420 Comparator | Feb 2009 → May 2011 | peripheral arterial disease | Sanofi | Completed | Met primary |
| Phase 3 | NCT01500434 Background | Feb 2009 → Mar 2011 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00823212 Background | Jan 2009 → Sep 2010 | coronary atherosclerosis | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00821834 Comparator | Dec 2008 → Aug 2010 | coronary artery disorder, myocardial infarction | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT03062319 Comparator | Apr 2017 → Jul 2023 | atherosclerosis, atrial fibrillation, ischemic stroke | National Hospital Organization Osaka National Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01589978 Background | May 2012 → Aug 2014 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01208714 Comparator | Dec 2010 → Dec 2015 | renal artery obstruction | University Hospital Padova | Unknown | No outcome recorded |
| Phase 4 | NCT01214941 Comparator | Sep → Dec 2010 | — | Turku University Hospital | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ticlopidine | “Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice...” NCT00823212 ↗15“All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if...” NCT01208714 ↗ “Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is...” NCT01514227 ↗ “* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)” NCT01589978 ↗ “clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure).” NCT01510327 ↗ “with aspirin and a thienopyridine (clopidogrel or ticlopidine\]) beyond that described in the product labeling.” NCT00963781 ↗ “when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used” NCT01212302 ↗ “aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol” NCT03062319 ↗ “ticlopidine 250 mg twice daily” NCT01500434 ↗ “Ticlopidine” NCT01103440 ↗ |
| Known as | 4-C-32 | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | 53-32C | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | A brand name for ticlopidine is TICLID. | “A brand name for ticlopidine is TICLID.” NCT01510327 ↗ |
| Known as | Ipaton | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | NSC-759165 | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | Ticlid | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | TICLID (ticlopidine) | “TICLID (ticlopidine)” NCT01589978 ↗ |
| Known as | Ticlopidin-puren | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | Ticlopidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | Ticlopidine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Known as | ticlopidine hydrochloride | “This is a multicenter, randomized, double-blind clinical trial of ticlopidine hydrochloride (500mg/day) and aspirin (650mg/day) in African-American patients with recent...” NCT00004727 ↗1“ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily” NCT02133989 ↗ |
| Known as | Tiklid | ChEMBL registry synonym — accepted as the source's own label CHEMBL833 ↗ |
| Action | Inhibit | “Ticlopidine increased exposure to tramadol, reduced its renal clearance and inhibited the formation of M1, most likely via inhibition of CYP2B6 and/or CYP2D6.” PMID 23099620 ↗ Oct 20121“Purinergic receptor P2Y12 antagonist” CHEMBL833 ↗ |
| Modality | Small molecule | — CHEMBL833 ↗ |
| Route | Oral | “Route: oral” NCT00821834 ↗ |
| Target | CYP2B6 | “Ticlopidine increased exposure to tramadol, reduced its renal clearance and inhibited the formation of M1, most likely via inhibition of CYP2B6 and/or CYP2D6.” PMID 23099620 ↗ Oct 2012 |
| Target | CYP2D6 | “Ticlopidine increased exposure to tramadol, reduced its renal clearance and inhibited the formation of M1, most likely via inhibition of CYP2B6 and/or CYP2D6.” PMID 23099620 ↗ Oct 2012 |
| Target | P2RY12 | “Purinergic receptor P2Y12 antagonist” CHEMBL833 ↗ |